Study of a new drug for atypical hemolytic uremic syndrome
Treatments studied
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine for people with a rare blood disorder called atypical hemolytic uremic syndrome (aHUS) that is still active despite other treatments. The drug aims to stop the ongoing damage to blood cells and kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have aHUS that is not responding to current treatment or has come back.
- You must have signs of active disease, like low platelets, anemia, and kidney injury.
- You must be willing to get vaccinated against meningitis before starting the drug.
- You must use effective birth control during the study if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called NM8074 for a type of blood vessel inflammation called ANCA-associated vasculitis. It's for people whose vasculitis is active and needs a stronger treatment like cyclophosphamide or rituximab.
This trial tests an investigational drug called NM8074 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet been treated with complement inhibitors. The goal is to see if NM8074 can reduce red blood cell destruction and improve anemia, potentially reducing the need for blood transfusions.
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
This study tests a new medicine called INM004 in children with STEC-HUS, a serious illness that damages the kidneys and blood cells. It may help speed up recovery and prevent complications.
This trial tests a new investigational drug called NM8074 for people with PNH whose disease is not well controlled on Soliris. It aims to see if this new treatment can improve their anemia and reduce the need for blood transfusions.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
Hear when a new aHUS - Atypical Hemolytic Uremic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.